Skip to Content
Morningstar

Clinuvel Pharmaceuticals Ltd CUV

Morningstar Rating
Unlock
Stock XASX Rating as of
A$14.57 −0.42 (2.80%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Clinuvel Shares Appear Undervalued as Sales in Core Product Continue to Grow

Shane Ponraj

Clinuvel’s strategy revolves around expanding its direct distribution for adult erythropoietic protoporphyria, or EPP, patients. This involves training and collaborating with doctors and accrediting the specialist skin centers they practice in to prescribe Scenesse. By focusing on distribution, Scenesse is more accessible to a greater number of patients, and supportive of organic top-line growth.

Read Full Report

Price vs Fair Value

View History
CUV is trading at a 17% discount.
Price
A$14.89
Fair Value
A$85.00
Uncertainty
High
1-Star Price
A$17.80
5-Star Price
A$46.20
Economic Moat
Tgpt
Capital Allocation
Qqwfdrjd

Bulls Say, Bears Say

Bulls

Scenesse is the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called EPP and is fairly protected in the near-term from competition.

Bears

There is high uncertainty on the success and timing of Clinuvel’s efforts to diversify its earnings beyond its single product, Scenesse, currently approved for the single niche EPP adult market.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CUV is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
A$14.99
Day Range
A$14.56–15.20
52-Week Range
A$12.96–21.53
Bid/Ask
A$14.56 / A$15.00
Market Cap
A$730.35 Mil
Volume/Avg
54,613 / 144,958

Key Statistics

Price/Earnings (Normalized)
19.08
Price/Sales
9.76
Dividend Yield (Trailing)
0.33%
Dividend Yield (Forward)
0.33%
Total Yield
0.33%

Company Profile

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
16
Website
https://www.clinuvel.com

Competitors

Valuation

View More
Metric
CUV
AVH
ABBV
Price/Earnings (Normalized)
 19.08—15.11
Price/Book Value
 4.214.5728.62
Price/Sales
 9.764.395.48
Price/Cash Flow
 18.75—14.86
Price/Earnings
CUV
AVH
ABBV

Financial Strength

Metric
CUV
AVH
ABBV
Quick Ratio
 6.387.350.63
Current Ratio
 6.867.880.87
Interest Coverage
 11.03−30.103.57
Quick Ratio
CUV
AVH
ABBV

Profitability

Metric
CUV
AVH
ABBV
Return on Assets (Normalized)
 19.77%−37.61%14.54%
Return on Equity (Normalized)
 23.18%−50.88%150.11%
Return on Invested Capital (Normalized)
 22.09%−44.09%28.30%
Return on Assets
CUV
AVH
ABBV
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRRlnxmfmsNgqnl$554.7 Bil
VRTX
Vertex Pharmaceuticals IncRnwwctztwMbctyzc$102.7 Bil
REGN
Regeneron Pharmaceuticals IncRvxdgmxWfjzyg$97.8 Bil
MRNA
Moderna IncSthjcspbYdlb$41.3 Bil
ARGX
argenx SE ADRCjscpxtyPln$22.3 Bil
BNTX
BioNTech SE ADRJzmcnkcgMngk$21.0 Bil
ALNY
Alnylam Pharmaceuticals IncCsynqqcmGykrsq$18.2 Bil
BMRN
Biomarin Pharmaceutical IncFwxmwwmbjCmcjn$15.4 Bil
RPRX
Royalty Pharma PLC Class AWdqwwjnxqRrfjc$12.5 Bil
INCY
Incyte CorpRjjpfdjmhXcjxy$11.6 Bil

Sponsor Center